PE20130199A1 - Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores - Google Patents
Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumoresInfo
- Publication number
- PE20130199A1 PE20130199A1 PE2012002019A PE2012002019A PE20130199A1 PE 20130199 A1 PE20130199 A1 PE 20130199A1 PE 2012002019 A PE2012002019 A PE 2012002019A PE 2012002019 A PE2012002019 A PE 2012002019A PE 20130199 A1 PE20130199 A1 PE 20130199A1
- Authority
- PE
- Peru
- Prior art keywords
- robo1
- protein
- fusion protein
- tumor treatment
- refers
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 101710157963 Protein RoBo-1 Proteins 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- SQEHCNOBYLQFTG-UHFFFAOYSA-M lithium;thiophene-2-carboxylate Chemical compound [Li+].[O-]C(=O)C1=CC=CS1 SQEHCNOBYLQFTG-UHFFFAOYSA-M 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Abstract
SE REFIERE A UNA PROTEINA RECOMBINANTE Robo-Fc QUE COMPRENDE: A) EL DOMINIO EXTRACELULAR DE LA ISOFORMA b DE LA PROTEINA Robo1 QUE COMPRENDE LOS DOMINIOS INMUNOGLOBULINA Ig1 Y Ig2, Y PRESENTA 80% DE IDENTIDAD CON LA SECUENCIA SEQ ID Nº 2; B) UN CONECTOR; Y C) UN DOMINIO Fc DE LA INMUNOGLOBULINA G4 HUMANA QUE CONTIENE LAS MUTACIONES S241P Y L248E, Y ESTA AUSENTE LA LISINA DE LA POSICION C-TERMINAL PARA AUMENTAR LA ESTABILIDAD DE LA PROTEINA, ELIMINAR LA ACTIVIDAD EFECTORA RESIDUAL DEL DOMINIO Fc O AUMENTAR LA HOMOGENEIDAD DURANTE SU PRODUCCION. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL PARA EL TRATAMIENTO DE ENFERMEDADES DONDE SE SOBREEXPRESA UNA PROTEINA SLIT TAL COMO CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1052829A FR2958936A1 (fr) | 2010-04-14 | 2010-04-14 | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130199A1 true PE20130199A1 (es) | 2013-03-09 |
Family
ID=42830780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002019A PE20130199A1 (es) | 2010-04-14 | 2011-04-08 | Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9493529B2 (es) |
| EP (1) | EP2558489A1 (es) |
| JP (1) | JP5858442B2 (es) |
| KR (1) | KR20130059329A (es) |
| CN (1) | CN102884076A (es) |
| AR (1) | AR080891A1 (es) |
| AU (1) | AU2011239839B2 (es) |
| BR (1) | BR112012026020A2 (es) |
| CA (1) | CA2796303A1 (es) |
| CL (1) | CL2012002879A1 (es) |
| CR (1) | CR20120508A (es) |
| DO (1) | DOP2012000265A (es) |
| EA (1) | EA201291044A1 (es) |
| EC (1) | ECSP12012230A (es) |
| FR (1) | FR2958936A1 (es) |
| GT (1) | GT201200275A (es) |
| IL (1) | IL222382A (es) |
| MA (1) | MA34221B1 (es) |
| MX (1) | MX338981B (es) |
| NI (1) | NI201200155A (es) |
| PE (1) | PE20130199A1 (es) |
| PH (1) | PH12012502044A1 (es) |
| SG (1) | SG184529A1 (es) |
| TN (1) | TN2012000473A1 (es) |
| TW (1) | TW201142024A (es) |
| UY (1) | UY33334A (es) |
| WO (1) | WO2011128561A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1064093C (zh) | 1993-04-05 | 2001-04-04 | 达金工业株式会社 | 聚四氟乙烯棉状物及其制造方法 |
| UY33833A (es) * | 2010-12-23 | 2012-07-31 | Sanofi Sa | Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma |
| CA2860558C (en) | 2012-01-05 | 2021-03-02 | Boston Medical Center Corporation | Slit-robo signaling for diagnosis and treatment of kidney disease |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| CN107298715B (zh) * | 2016-04-15 | 2021-05-04 | 阿思科力(苏州)生物科技有限公司 | Slit2D2-嵌合抗原受体及其应用 |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| WO2017194597A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| ES2909833T3 (es) | 2016-05-11 | 2022-05-10 | Cytiva Bioprocess R & D Ab | Método de limpieza y/o desinfección de una matriz de separación |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| MX2019014480A (es) * | 2017-06-02 | 2020-01-23 | Pfizer | Proteinas recombinantes robo2, composiciones, metodos y usos de las mismas. |
| US11406682B2 (en) | 2017-08-24 | 2022-08-09 | Bar-Ilan University | Roundabout (Robo) receptor inhibitors and uses thereof |
| JP7340027B2 (ja) * | 2019-02-27 | 2023-09-06 | デウン ファーマシューティカル カンパニー リミテッド | アルブミンと結合したＳｌｉｔ３タンパク質のＬＲＲＤ２を含む骨関連疾患の予防または治療用組成物 |
| AU2020262256B2 (en) | 2019-04-23 | 2026-01-15 | The Regents Of The University Of California | Compositions and methods useful in promoting milk production |
| WO2025056020A1 (zh) * | 2023-09-14 | 2025-03-20 | 北京拓界生物医药科技有限公司 | 包含robo结构域的蛋白及其医药用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| US20060122373A1 (en) | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
| WO1999020764A1 (en) * | 1997-10-20 | 1999-04-29 | The Regents Of The University Of California | Robo: a family of polypeptides and nucleic acids involved in nerve guidance |
| CA2324284A1 (en) * | 1998-04-02 | 1999-10-14 | Rigel Pharmaceuticals, Inc. | Peptides causing formation of compact structures |
| CA2416732C (en) * | 2000-08-02 | 2016-02-09 | Brad St. Croix | Endothelial cell expression patterns |
| EP2316853A3 (en) | 2002-03-08 | 2011-10-05 | Shanghai Institutes for Biological Sciences, CAS | Detection and modulation of slit and roundabout (robo) mediated angiogenesis and uses thereof |
| JP4643450B2 (ja) * | 2003-08-08 | 2011-03-02 | 株式会社ペルセウスプロテオミクス | 癌高発現遺伝子 |
| CN1926237A (zh) * | 2004-01-28 | 2007-03-07 | 森托尼克斯制药有限公司 | 用于治疗不育症的异二聚体促卵泡激素－Fc(FSH－Fc)融合蛋白 |
| EP2738178A1 (en) * | 2006-04-05 | 2014-06-04 | AbbVie Biotechnology Ltd | Antibody purification |
| AR063975A1 (es) | 2006-11-28 | 2009-03-04 | Centelion | Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada |
| US20130195881A1 (en) * | 2007-04-27 | 2013-08-01 | Sanjaya Singh | Potent, stable and non-immunosuppressive anti-cd4 antibodies |
| DK2195023T3 (en) | 2007-08-29 | 2018-06-18 | Sanofi Sa | HUMANIZED ANTI-CXCR5 ANTIBODIES, DERIVATIVES THEREOF AND THEIR USE |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
-
2010
- 2010-04-14 FR FR1052829A patent/FR2958936A1/fr active Pending
-
2011
- 2011-04-08 AU AU2011239839A patent/AU2011239839B2/en not_active Ceased
- 2011-04-08 US US13/641,012 patent/US9493529B2/en active Active
- 2011-04-08 PE PE2012002019A patent/PE20130199A1/es not_active Application Discontinuation
- 2011-04-08 MA MA35354A patent/MA34221B1/fr unknown
- 2011-04-08 KR KR1020127026724A patent/KR20130059329A/ko not_active Ceased
- 2011-04-08 PH PH1/2012/502044A patent/PH12012502044A1/en unknown
- 2011-04-08 JP JP2013504311A patent/JP5858442B2/ja not_active Expired - Fee Related
- 2011-04-08 SG SG2012075107A patent/SG184529A1/en unknown
- 2011-04-08 EP EP11719346A patent/EP2558489A1/fr not_active Withdrawn
- 2011-04-08 CN CN2011800238283A patent/CN102884076A/zh active Pending
- 2011-04-08 BR BR112012026020A patent/BR112012026020A2/pt not_active IP Right Cessation
- 2011-04-08 WO PCT/FR2011/050811 patent/WO2011128561A1/fr not_active Ceased
- 2011-04-08 MX MX2012011822A patent/MX338981B/es active IP Right Grant
- 2011-04-08 CA CA2796303A patent/CA2796303A1/fr not_active Abandoned
- 2011-04-08 EA EA201291044A patent/EA201291044A1/ru unknown
- 2011-04-13 AR ARP110101252A patent/AR080891A1/es unknown
- 2011-04-14 UY UY0001033334A patent/UY33334A/es not_active Application Discontinuation
- 2011-04-14 TW TW100113039A patent/TW201142024A/zh unknown
-
2012
- 2012-09-28 TN TNP2012000473A patent/TN2012000473A1/fr unknown
- 2012-10-05 DO DO2012000265A patent/DOP2012000265A/es unknown
- 2012-10-08 EC ECSP12012230 patent/ECSP12012230A/es unknown
- 2012-10-08 CR CR20120508A patent/CR20120508A/es unknown
- 2012-10-11 IL IL222382A patent/IL222382A/en not_active IP Right Cessation
- 2012-10-11 GT GT201200275A patent/GT201200275A/es unknown
- 2012-10-12 NI NI201200155A patent/NI201200155A/es unknown
- 2012-10-12 CL CL2012002879A patent/CL2012002879A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9493529B2 (en) | 2016-11-15 |
| US20130039912A1 (en) | 2013-02-14 |
| PH12012502044A1 (en) | 2017-07-26 |
| IL222382A (en) | 2016-06-30 |
| FR2958936A1 (fr) | 2011-10-21 |
| JP2013523172A (ja) | 2013-06-17 |
| AR080891A1 (es) | 2012-05-16 |
| CL2012002879A1 (es) | 2013-03-22 |
| DOP2012000265A (es) | 2013-02-28 |
| BR112012026020A2 (pt) | 2016-06-28 |
| MX2012011822A (es) | 2012-11-12 |
| ECSP12012230A (es) | 2012-11-30 |
| CN102884076A (zh) | 2013-01-16 |
| KR20130059329A (ko) | 2013-06-05 |
| JP5858442B2 (ja) | 2016-02-10 |
| IL222382A0 (en) | 2012-12-31 |
| MX338981B (es) | 2016-05-06 |
| NI201200155A (es) | 2013-02-05 |
| CR20120508A (es) | 2012-11-01 |
| EP2558489A1 (fr) | 2013-02-20 |
| GT201200275A (es) | 2014-01-24 |
| AU2011239839B2 (en) | 2015-08-20 |
| CA2796303A1 (fr) | 2011-10-20 |
| UY33334A (es) | 2011-12-01 |
| EA201291044A1 (ru) | 2013-04-30 |
| TW201142024A (en) | 2011-12-01 |
| TN2012000473A1 (fr) | 2014-01-30 |
| SG184529A1 (en) | 2012-11-29 |
| WO2011128561A1 (fr) | 2011-10-20 |
| AU2011239839A1 (en) | 2012-11-08 |
| MA34221B1 (fr) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130199A1 (es) | Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores | |
| CY1126072T1 (el) | Περιοχες gla ως θεραπευτικοι παραγοντες | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| EA201790063A1 (ru) | Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения | |
| ECSP17073650A (es) | Proteínas de fusión | |
| PH12015502125A1 (en) | Il-22 polypeptides and il-22 fc fusion proteins and methods of use | |
| GT201500049A (es) | Proteinas de fusiòn para el tratamiento de un sìndrome metàbolico | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| MX2018009524A (es) | Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso. | |
| MX2016015868A (es) | Metodos y composiciones para el tratamiento de trastornos con polipeptidos de folistatina. | |
| CU20140034A7 (es) | Proteínas de fusión para tratar trastornos metabólicos | |
| PE20141166A1 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| CU20120116A7 (es) | Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5 | |
| EA201491856A1 (ru) | Терапевтическое применение белков фактора роста фибробластов 21 | |
| PE20161440A1 (es) | Variantes del anticuerpo anti-factor d y sus usos | |
| EA201690469A1 (ru) | Слитый белок | |
| PE20200894A1 (es) | Polipeptidos variantes del factor de crecimiento tipo insulina 1 | |
| BR112013032088A2 (pt) | "polipeptídeo, composição farmacêutica e seu uso" | |
| EA201490901A1 (ru) | Линкеры на основе тирозина для свободного соединения пептидов | |
| EP4306123A3 (en) | Saposin-a derived peptides and uses thereof | |
| MX2022003531A (es) | Polipeptidos de fusion dap10/dap12. | |
| PE20141479A1 (es) | Senuelos humanos notch1 | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| PL394618A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| MX2018009499A (es) | Anticuerpos monoclonales especificos de egfl6 y metodos de su uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |